Retina Synthesis

We discuss the use of suprachoroidal gene therapy for eyes with diabetic retinopathy without macular edema with Dr. Dennis Marcus, Clinical Professor of Ophthalmology, Medical College of Georgia.

We review surgical techniques for sub retinal gene therapy with Dr. Lejla Vajzovic.

Dr. Yasha Modi, Associate Professor of Ophthalmology at the NYU Langone Medical Center provides an evidence based review of management of retinal venous occlusion.

We discuss the use of a cooling probe as primary anesthesia for intravitreal injection with Ajay Kuriyan, MD, Associate Professor of Ophthalmology, Wills Eye Hospital.

We discuss blockade of complement component C1q as a novel treatment for geographic atrophy with Donald Fong, MD, Vice President Ophthalmology Clinical Development, Annexon.

We discuss clinical trials using CNTF to treat MacTel Type 2 with Dr. John Pollack, Chief Medical Officer of Neurotech Pharmaceuticals.

We asked Dr. Mohamed Genead, Chief Medical Officer, Nanoscope Therapeutics to discuss and review the latest developments in optogenetic gene therapy for retinal degenerations. 

Dr. Robert Avery of California Retina Consultants reviews the latest status of gene therapy for AMD and DR.

Many drugs are currently being investigated in attacking or supplementing the complement cascade for the treatment of geographic atrophy. We review, with the help of Dr. Johanna Seddon, Professor of Ophthalmology, University of Massachusetts Medical Center the basic biology that underlies these treatments, and assess their clinical potential.

We interview Dr. Caroline Baumal, Professor Of Ophthalmology at New England Eye Center and the Tufts University School of Medicine and we review clinical applications and safety results of brolucizumab.

Dr. Linda Lam, Professor of Ophthalmology at the USC Roski Eye Institute talks about augmented reality for low vision and unique surgical applications.

Dr Barone describes the mission of Gemini and discusses recent preliminary data from the ongoing Phase 2a REGATTA study

We knew that anti-VEGF therapy favorably affected the natural history of moderate or severe  nonproliferation retinopathy. As a result of DRCR network Protocol W, we now know that careful observation with treatment of complications as they develop produces visual acuity results at 2 years similar to prophylactic therapy.

Dr. Dilsher Dhoot discusses patient outcomes in the PANORAMA trial looking at areas of non perfusion.

Dr. Jamie Dananberg, Chief Medical Officer of Unity Biotechnology discusses their strategy of selectively targeting senescent retinal vascular endothelial cells for a more long lasting effect on altering the pathophysiology of diabetic eye disease.

A Real World Clinical Trial Employing AI Dr. Anat Loewenstein presents data demonstrating the effectiveness of the Notal Home OCT System with artificial intelligence for real world monitoring of eyes undergoing anti-VEGF therapy.

Dr. Usha Chakravarthy, Professor of Ophthalmology, Queen's University Belfast presents characteristics of macular neovascularization at its earliest diagnosis.

Diana Do, MD, Professor of Ophthalmology, Vice Chair Clinical Affairs, Department of Ophthalmology, Stanford University, Byers Eye Institute.

In this episode, Dr. David Boyer discusses a Phase 2 trial studying intravitreal injection of retinal progenitor cells for treatment of eyes with retinitis pigmentosa.

Dr. Carmen Puliafito interviews Andrew Moshfeghi, MD on a topic: Tyrosine Kinase Inhibitor Delivery by Hydrogel for Treatment of Wet AMD

Join us as Dr. Carmen Puliafito joins in a discussion with Carl Regillo, MD, Director of Retina Serivce, Wills Eye Institute on the topic of Phase 3 Results from the Port Delivery System (PDS) Phase 3 Trial.

Join us as Dr. Charles Wykoff dives in a discussion with Arshad Khanani MD, MA in a discussion on Faricimab in the TENAYA and LUCERN Phase 3 nAMD Trials: Interpreting the Results

Join us as Dr. Carmen Puliafito and Charles Wykoff MD, PhD speak about the results. 1 of 3 total parts to "Interpreting Faricimab Phase 3 Data in DME & nAMD"

Join us in a discussion with Dr. Charles Wykoff & Karl Csaky MD, PhD on Faricimab for DME and nAMD. Interpreting the Durability Signals from the Phase 3 Programs.

Dr. Francois discusses the epidemiology of geographic atrophy, the pathophysiology of complement inhibition in the treatment of GA, and the latest information on Apellis' Phase 2 and Phase 3 clinical trials.